ENHERTU

Google image searchProduct monograph

Active ingredient

trastuzumab deruxtecan, 100 MG/VIAL

DIN: 02514400

Dosage form(s): POWDER FOR SOLUTION

Route(s) of administration: INTRAVENOUS

Description: SINGLE-USE VIAL

Schedule: Prescription / Schedule D

Company: ASTRAZENECA CANADA INC

Date: 09-JUL-2021

ATC:

• L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
• L01F — MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES (ATC, ATC/DDD)
• L01FD — HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors (ATC, ATC/DDD)
• L01FD04 — TRASTUZUMAB DERUXTECAN (ATC/DDD)

External Links for Enhertu

Search on Google

• Enhertu side effects
• Enhertu dosage
• trastuzumab deruxtecan side effects
• trastuzumab deruxtecan dosage

Astrazeneca Canada Inc

Go to AstraZeneca website to see drug product details. Sometimes you can find enhertu photos and/or monograph. If you are a healthcare professional, you may need to enter your license number.